,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4710 Bellaire Boulevard,Suite 210,Bellaire,TX,77401,United States,832-742-1357,https://www.biopathholdings.com,Biotechnology,Healthcare,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",10,"{'maxAge': 1, 'name': 'Mr. Peter H. Nielsen MBA', 'age': 73, 'title': 'Co-Founder, Chairman, CEO, Pres, CFO & Treasurer', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 722678, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.404,0.41,0.3801,0.41,0.404,0.41,0.3801,0.41,0.0,1.359958,-0.3203125,130130,130130,357480,51560,51560,0.3801,0.405,1100,1100,4698682,0.35,3.85,0.7028,1.40685,0.0,0.0,USD,1422667,0.0,11420283,11460200,176014,409344,1690761600,1693440000,0.0154,0.00427,0.07166,0.22,0.0154,0.634,0.6466877,1672444800,1703980800,1688083200,-17008000,-2.28,-1.28,1:20,1547769600,-0.084,NCM,EQUITY,BPTH,BPTH,"Bio-Path Holdings, Inc.","Bio-Path Holdings, Inc.",1204641000,America/New_York,EDT,-14400000,0.41,12.0,12.0,12.0,12.0,2.0,buy,1,3444000,0.301,-16977000,168000,2.415,4.389,3.331,-0.77480006,-1.38485,-8870250,-15314000,0.0,0.0,0.0,USD,
1,4710 Bellaire Boulevard,Suite 210,Bellaire,TX,77401,United States,832-742-1357,https://www.biopathholdings.com,Biotechnology,Healthcare,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",10,"{'maxAge': 1, 'name': 'Mr. Douglas P. Morris', 'age': 66, 'title': 'Co-Founder, Director of Investor Relations, Sec. & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 110681, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.404,0.41,0.3801,0.41,0.404,0.41,0.3801,0.41,0.0,1.359958,-0.3203125,130130,130130,357480,51560,51560,0.3801,0.405,1100,1100,4698682,0.35,3.85,0.7028,1.40685,0.0,0.0,USD,1422667,0.0,11420283,11460200,176014,409344,1690761600,1693440000,0.0154,0.00427,0.07166,0.22,0.0154,0.634,0.6466877,1672444800,1703980800,1688083200,-17008000,-2.28,-1.28,1:20,1547769600,-0.084,NCM,EQUITY,BPTH,BPTH,"Bio-Path Holdings, Inc.","Bio-Path Holdings, Inc.",1204641000,America/New_York,EDT,-14400000,0.41,12.0,12.0,12.0,12.0,2.0,buy,1,3444000,0.301,-16977000,168000,2.415,4.389,3.331,-0.77480006,-1.38485,-8870250,-15314000,0.0,0.0,0.0,USD,
2,4710 Bellaire Boulevard,Suite 210,Bellaire,TX,77401,United States,832-742-1357,https://www.biopathholdings.com,Biotechnology,Healthcare,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",10,"{'maxAge': 1, 'name': 'Mr. Anthony  Price', 'title': 'Sr. VP of Fin., Accounting & Admin.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.404,0.41,0.3801,0.41,0.404,0.41,0.3801,0.41,0.0,1.359958,-0.3203125,130130,130130,357480,51560,51560,0.3801,0.405,1100,1100,4698682,0.35,3.85,0.7028,1.40685,0.0,0.0,USD,1422667,0.0,11420283,11460200,176014,409344,1690761600,1693440000,0.0154,0.00427,0.07166,0.22,0.0154,0.634,0.6466877,1672444800,1703980800,1688083200,-17008000,-2.28,-1.28,1:20,1547769600,-0.084,NCM,EQUITY,BPTH,BPTH,"Bio-Path Holdings, Inc.","Bio-Path Holdings, Inc.",1204641000,America/New_York,EDT,-14400000,0.41,12.0,12.0,12.0,12.0,2.0,buy,1,3444000,0.301,-16977000,168000,2.415,4.389,3.331,-0.77480006,-1.38485,-8870250,-15314000,0.0,0.0,0.0,USD,
3,4710 Bellaire Boulevard,Suite 210,Bellaire,TX,77401,United States,832-742-1357,https://www.biopathholdings.com,Biotechnology,Healthcare,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",10,"{'maxAge': 1, 'name': 'Dr. Ana Tari Ashizawa Ph.D., MBA', 'title': 'Sr. VP of Research, Devel. & Clinical Design', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.404,0.41,0.3801,0.41,0.404,0.41,0.3801,0.41,0.0,1.359958,-0.3203125,130130,130130,357480,51560,51560,0.3801,0.405,1100,1100,4698682,0.35,3.85,0.7028,1.40685,0.0,0.0,USD,1422667,0.0,11420283,11460200,176014,409344,1690761600,1693440000,0.0154,0.00427,0.07166,0.22,0.0154,0.634,0.6466877,1672444800,1703980800,1688083200,-17008000,-2.28,-1.28,1:20,1547769600,-0.084,NCM,EQUITY,BPTH,BPTH,"Bio-Path Holdings, Inc.","Bio-Path Holdings, Inc.",1204641000,America/New_York,EDT,-14400000,0.41,12.0,12.0,12.0,12.0,2.0,buy,1,3444000,0.301,-16977000,168000,2.415,4.389,3.331,-0.77480006,-1.38485,-8870250,-15314000,0.0,0.0,0.0,USD,
